Dihexa

Description

Dihexa

Also known as: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

Dihexa is an experimental peptide derived from Angiotensin IV, currently under investigation for its possible impact on memory, neuroplasticity, synapse formation, and mechanisms involved in brain repair. Rather than acting as a conventional stimulant-type nootropic, it is being studied primarily for its influence on the HGF/c-Met signaling pathway, which could support the development and reinforcement of neural connections. The compound has drawn considerable interest within cutting-edge nootropic and longevity research circles due to its potential to aid cognitive recovery and promote the regeneration of nerve tissue.

•Status: Currently in preclinical development as a research compound. Its prodrug form, fosgonimeton, is undergoing clinical trials for Alzheimer’s and Parkinson’s diseases. Evidence to date comes primarily from animal studies.
•Typical dosage: 5–20 mg per day, administered orally, sublingually, or intranasally. Often taken once daily, with effects potentially lasting up to 10 days.
•Studied for: Improving memory, enhancing cognitive function, and supporting neuroplasticity.